More news and the news contents can be obtained from our website

Transcription

1 Investor News 2009 Bayer AG Investor Relations Leverkusen Germany More news and the news contents can be obtained from our website Date December 10, 2009 December 07, 2009 December 06, 2009 December 1, 2009 December 1, 2009 November 30, 2009 November 19, 2009 News Clinical Programs with Riociguat in Pulmonary Hypertension Well on Track - Encouraging top-line data from the first Phase II study in pulmonary hypertension owing to interstitial lung disease (PH-ILD) - First Phase II study in pulmonary hypertension owing to chronic obstructive pulmonary disease (PH-COPD) successfully completed Visanne cleared for market launch in Europe as new treatment option for endometriosis Treatment of Venous Thromboembolism (VTE): Phase III EINSTEIN-Extension Study of Bayer's Rivaroxaban Shows Significant Benefit in the Prevention of Secondary Symptomatic VTE - Impressive 82% Relative Risk Reduction (RRR) in the Recurrence of Symptomatic VTE over Patients Treated with Placebo - Positive Benefit-Risk profile for Rivaroxaban Confirmed - First Phase III Data in the Chronic Setting to be Presented as a Late-Breaker at the Annual Meeting of the American Society of Hematology - Ongoing Discussions with FDA on Complete Response Letter for VTE Prevention After Total Knee and Hip Replacement Surgery Development of new BiTE antibody for treatment of solid tumors Bayer Schering Pharma to collaborate with Micoromet on novel approach to cancer therapy Bayer s Betaferon approved in China for treatment of multiple sclerosis Launch planned by mid 2010 Bayer starts Phase III trial with Florbetaben - Detection of bea-amyloid plaques in Alzheimer patients possible - Florbetaben could improve current diagnostic tools Positive results from chronic study with Bayer s rivaroxaban will be presented as a late breaker at ASH 2009 Endpoints met in EINSTEIN-Extension trial in the secondary prevention of recurrent symptomatic VTE November 2, 2009 Successful purchase of trait platform with extensive product pipeline: Bayer CropScience completes acquisition of biotech company Athenix Corp. Purchase price of USD 365 million plus milestones October 27, 2009 Renewed year-on-year growth in underlying EBITDA in the third quarter of 2009: Bayer back on the uptrend - HealthCare again strong - weak quarter at CropScience MaterialScience substantially improved - Group sales EUR 7,392 million (minus 7.0 percent) - EBITDA before special items EUR 1,499 million (plus 0.4 percent) - Net income EUR 249 million (minus 10.1 percent) - Net cash flow EUR 1,517 million (plus 22.9 percent) - Full-year Group forecast confirmed October 23, 2009 Bayer and Onyx Initiate Phase III Trial of Nexavar in Patients with Non- Responsive Thyroid Cancer - 1 -

2 October 22, 2009 October 9, 2009 October 5, 2009 September 30, 2009 September 23, 2009 September 22, 2009 September 17, 2009 September 17, 2009 September 15, 2009 September 03, 2009 September 02, 2009 Swiss regulatory authority Swissmedic announces results of its analysis of current studies on the risks of hormonal contraceptives: The risk of venous thromboembolism for drospirenone containing oral contraceptives is comparable to the risk of other oral contraceptives available on the market Improvement in orders Bayer MaterialScience AG ends reduced working hours at German sites - Rates of pay to be raised again - Solidarity-based solution has proved its worth - Opening clause in collective agreement applied from February to the end of October 2009 Phase-III data presented at the World Congress of Gynecology & Obstetrics (FIGO): Bayer's novel oral contraceptive Qlaira significantly reduces heavy menstrual bleeding Results also confirm significant improvement in blood iron levels Results Reported for Exploratory Phase II Trial of Nexavar in Combination with Chemotherapeutic Agent Paclitaxel for Treatment of Advanced Breast Cancer Preliminary results require further analysis and interpretation Phase II Study in Advanced Breast Cancer: Nexavar in Combination with Chemotherapy Demonstrates 74 Percent Improvement in Progression-Free Survival First presentation of results at joint ECCO-ESMO congress in Berlin, Germany Results of a Phase II study in Renal Cell Carcinoma (RCC): Bayer's Novel Anti-Cancer Compound Regorafenib (BAY ) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients - Presentation of complete results at joint 15th ECCO and 34th ESMO Multidisciplinary Congress - Confirmation of topline data presented at ASCO 2009 Greater focus on future technologies: Bayer CropScience accelerates expansion of biotech and seed business with investments of around EUR 3.5 billion through BioScience sales of EUR 1.4 billion targeted for Biotech licensing agreements tap into business potential in excess of EUR 500 million - Peak sales potential of new crop protection actives raised to EUR 1.25 billion Joint 15th ECCO and 34th ESMO Multidisciplinary Congress: Bayer Announces New Data on Oncology Portfolio To Be Presented at the ECCO-ESMO Congress 2009 Marketed Products and Pipeline Compounds Highlighted at Presentation Sessions Bayer Supervisory Board decides company's future management line-up: Dr. Marijn E. Dekkers to be new CEO of Bayer from October 1, Werner Wenning extends his contract by eight months - CFO Klaus Kühn to retire on April 30, Werner Baumann to be new CFO - BHC CEO Arthur J. Higgins to leave Bayer at his own request Bayer and Algeta Enter Global Agreement for Development and Commercialization of Treatment for Bone Metastases in Cancer Patients Phase III compound represents potential therapy for life-threatening condition Bayer Acquires Two Prescription Dermatology Product Lines from SkinMedica in the U.S. - Bayer subsidiary Intendis expands presence in the U.S. - Asset purchase agreement signed for marketed prescription products Desonate and NeoBenz Micro - 2 -

3 August 30, 2009 August 19, 2009 Bayer Committed to Prevention of Arterial Thrombosis: Bayer Completes Enrollment into Major Phase III Study with Rivaroxaban (ROCKET AF) - ROCKET AF study compares rivaroxaban to warfarin in the prevention of stroke and non-cns systemic embolism in patients with Atrial Fibrillation - Bayer Schering Pharma supports Thrombosis Research Institute's launch of GARFIELD - a global patient Registry to evaluate 'real life' outcomes in the prevention of stroke in patients with Atrial Fibrillation - Fast Track designation for rivaroxaban development program in the secondary prevention of cardiovascular events in patients with Acute Coronary Syndrome recognizes high unmet medical need. Trait platform with extensive product pipeline to deliver innovative solutions for farmers: Bayer CropScience acquires US biotech company Athenix Corp. August 19, 2009 New Levitra formulation submitted for registration in the EU First orodispersible tablet for the treatment of erectile dysfunction July 29, 2009 Interim report for the second quarter of 2009: Bayer robust in a difficult environment - HealthCare strong - further growth at CropScience - MaterialScience stabilized - Group sales EUR 8,009 million (minus 5.9 percent) - EBITDA before special items EUR 1,765 million (minus 6.9 percent) - EBIT before special items EUR 1,101 million (minus 11.8 percent) - Group net income EUR 532 million (minus 7.3 percent) - Net cash flow EUR 1,399 million (plus 57.4 percent) - Earnings targets for full year 2009 confirmed July 22, 2009 July 21, 2009 July 16, 2009 July 14, 2009 July 13, 2009 July 09, 2009 July 08, 2009 July 07, 2009 July 01, 2009 June 29, 2009 June 25, 2009 Nexavar in Combination with Chemotherapy Shown To Extend Progression- Free Survival in Patients with Advanced Breast Cancer Statistically Significant Results Reported from a Phase II Study Combining Two Oral Cancer Therapies Long-term cooperation with leading Australian research institute CSIRO: Bayer CropScience expands global R&D activities in seeds and traits by setting up new research focus area in cereals Superior solutions for wheat farmers could be available as early as 2015 Bayer MaterialScience lifts force majeure for TDI in Europe New Drug Application for Rivaroxaban in the U.S.: Update on Status of Rivaroxaban Complete Response Letter From U.S. FDA International Conference on Alzheimer's Disease (ICAD): Bayer presents positive Phase II data with florbetaben - Potential to visualize beta-amyloid plaques in Patients with Alzheimer's disease demonstrated - Florbetaben may innovate the diagnostic capabilities Expansion of diabetes portfolio in growth market China: Bayer acquires exclusive rights to Bioton's insulin SciLin Bayer submits first-in-class estradiol-based oral contraceptive for approval in the U.S. FDA approval requested for oral contraception and treatment of heavy and/or prolonged menstrual bleeding Bayer MaterialScience declares force majeure for TDI in Europe Bayer files patent infringement lawsuit against Teva Bayer CropScience and Monsanto sign cross licensing agreement on herbicide tolerance traits in rapeseed/canola New choices for corn and soybean farmers worldwide: Bayer CropScience and DuPont expand collaboration with broad license agreements - 3 -

4 June 02, 2009 June 01, 2009 May 30, 2009 May 28, 2009 May 28, 2009 May 22, 2009 May 20, 2009 May 19, 2009 May 15, 2009 May 14, 2009 May 05, 2009 Bayer HealthCare and Genzyme Finalize Strategic Alliance Agreement Bayer and Onyx Initiate Phase III Trial of Nexavar in Non-small Cell Lung Cancer 45th American Society of Clinical Oncology Annual Meeting (ASCO): Bayer Schering Pharma Announces New Data on Novel Anti-cancer Compound BAY Venous Blood Clot Prevention after Hip or Knee Replacement Surgery: U.S. FDA Issues Complete Response Letter for Rivaroxaban No new clinical or non-clinical studies to be conducted as a pre-requisite for approval Phase III Trial Started to Evaluate Combination Therapy of Nexavar and Tarceva in Patients with Liver Cancer Milestone for the cotton-pipeline U.S. Department of Agriculture grants approval for Bayer CropScience's GlyTol Nexavar Approved in Japan for the Treatment of Advanced Liver Cancer American Thoracic Society (ATS) congress, San Diego, USA: Bayer Schering Pharma presents positive results of phase II study with Riociguat Bayer and Onyx Announce Nexavar Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting Qlaira - innovative estradiol-based oral contraceptive available in Europe from May onwards A new oral contraceptive delivering the same estrogen as produced by the female body Bayer Schering Pharma is starting Phase III studies with an innovative low-dose contraceptive patch April 30, 2009 Bayer and Regeneron extend development program for VEGF Trap-Eye Two phase III studies in Central Retinal Vein Occlusion (CRVO) to begin in the second half of this year April 29, 2009 Bayer interim report for the first quarter of 2009 CropScience and Pharmaceuticals continue on a path of growth - Slump in business at MaterialScience leaves a distinct mark - Group sales: EUR 7,895 million (minus 7.5 percent) - EBITDA before special items: EUR 1,695 million (minus 22.4 percent) - EBIT before special items: EUR 1,017 million (minus 32.1 percent) - Net cash flow: EUR 693 million (plus 31.3 percent) April 28, 2009 April 27, 2009 March 31, 2009 March 23, 2009 March 19, 2009 Bayer and Ardea Biosciences Enter Global Agreement Focused on the Development of MEK Inhibitors for the Treatment of Cancer Phase III Trial of Nexavar in Chemotherapy-Naive Patients with Advanced Melanoma Does Not Meet Primary Endpoint Study stopped based on interim analysis Bayer HealthCare and Genzyme Corporation Enter New Strategic Agreement - Agreement improves profitability and strategic focus in key Bayer therapeutic areas - Licenses hematological cancer products to Genzyme - Continues co-development partnership for alemtuzumab in multiple sclerosis (MS) - Bayer maintains worldwide co-promotion rights for alemtuzumab in MS - distribution rights returned to Genzyme - Bayer to receive substantial licensing, milestone payments from Genzyme over the duration of the agreement Bayer issues corporate bond with a volume of EUR 1.3 billion Venous Blood Clot Prevention after Hip or Knee Replacement Surgery: U.S. FDA Advisory Committee supports favorable benefit-risk profile of Bayer's rivaroxaban - 4 -

5 March 03, 2009 February 27, 2009 February 12, 2009 February 09, 2009 January 07, earnings targets met Bayer: corporate strategy proves effective in a difficult environment - Sales increase by 1.6 percent to EUR 32,918 million - EBITDA before special items up 2.3 percent to EUR 6,931 million - EBIT before special items up 1.3 percent to EUR 4,342 million - Net income of EUR 1,719 million (2007: EUR 4,711 million) - Further earnings growth expected at HealthCare and CropScience in Sharp decline in earnings forecasted for MaterialScience - Significant reduction of net debt targeted Bayer proposes increased dividend for 2008 of EUR 1.40 per share Plans to switch from bearer shares to registered shares Bayer Schering Pharma to invest 100 million Euro in China to build a global R&D center Development of riociguat is progressing well: Bayer Schering Pharma Starts Phase III Program of New Drug Against Pulmonary Hypertension Visanne - new long-term treatment for endometriosis submitted for registration in Europe - 5 -